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Achieving hepatitis C virus (HCV) elimination by 2030 requires an increased linkage to care 
for people who inject drugs (PWID). Project ITTREAT was established to mitigate barriers to 
HCV care by providing an integrated service within a local drug and alcohol treatment (DAT) 
centre. 
Aim 
This study aimed to explore the experiences of clients and staff involved in Project ITTREAT 
and assess the facilitators and barriers to a community-based HCV service.  
Methods 
Between Oct 2014-Apr 2016, DAT attendees were interviewed using one-to-one semi-
structured interviews. DAT staff took part in focus groups. All data were recorded, 
transcribed verbatim and analysed using thematic content analysis.  
Results 
Fifteen DAT attendees with current/previous HCV infection were interviewed and 15 staff 
members contributed across two focus groups. DAT staff and attendees reported that 
Project ITTREAT facilitated access to HCV care by mitigating previous negative hospital-
based experiences. Other key facilitators were positive narratives around HCV care and DAT 
attendees being well engaged in their drug/alcohol recovery. Barriers included a lack of 
stability in DAT attendees, negative discourse around testing/treatment and stigma 
associated with attending the DAT to access HCV treatment in some who had successfully 
achieved drug rehabilitation.  
Conclusions 
Our findings indicate the positive impact of an integrated and personalised community-
based service delivered by a dedicated hepatitis nurse. This played a crucial role in reducing 
barriers to HCV care for PWID. Our work also highlights areas for future investment 
including non-DAT based community services and increasing awareness of new treatments 








Hepatitis C virus (HCV) is transmitted by direct blood-blood contact and can cause liver 
cirrhosis and cancer if left untreated (1). There is currently no effective vaccine. Injecting 
drug use (IDU) remains the most important risk factor for HCV acquisition and globally 67% 
of people who inject drugs (PWID) are hepatitis C antibody positive (2).  
Globally rates of viral hepatitis deaths (1.4 million/yr) are comparable to those of HIV (1.3 
million/yr), malaria (0.5 million/yr) and tuberculosis (1.2 million/yr) (3, 4). After the advent 
of the highly effective direct acting antivirals (DAA) (5), the WHO launched the Global Health 
Sector Strategy (GHSS) in 2016, with the aim of eliminating viral hepatitis as a major health 
burden by 2030 (3). This strategy tasked countries with diagnosing 90% and treating 80% of 
those with HCV by 2030 (3).   
In England, liver disease from HCV infection is a major health burden with approximately 
113,000 individuals infected (6).  Almost all those with chronic HCV infection in England 
(92%) have a history of IDU with approximately half of all PWIDs infected (6).  In the 2017 
Unlinked Anonymous Monitoring (UAM) survey, of those PWIDs aware of their HCV 
antibody status, 72% reported having ever seen a Hepatologist. Of these, 42% accepted and 
commenced treatment, 34% declined the offer of treatment and 23% were not offered 
treatment (7).  
Access to DAAs has been gradually rolled out via Operational Delivery Networks (ODNs), led 
by NHS England (8). Since DAAs first became available in 2014, treatment numbers have 
increased dramatically in England; from approximately 5100 people receiving HCV 
treatment annually (2008-2014) to 15, 506 between 2015-2017 (7). However, despite more 
PWIDs being aware that they have HCV infection (an estimated two thirds now know their 
status) (7), good evidence of the efficacy of DAAs in PWIDs (9, 10), and low rates of 
reinfection, the numbers of PWIDs accessing treatment remains low (7, 11-13). The 
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vulnerable and disenfranchised nature of PWIDs and poor engagement with hospital 
services undoubtedly contributes to this (14-16). 
Barriers to PWIDs accessing HCV treatment have been explored in a number of contexts and 
are summarised at the patient, provider and national levels in Figure 1 (17). If the UK is to 
achieve WHO targets, engaging, testing and treating this hard-to-reach cohort is essential. In 
the UK, intermittent HCV outreach programmes (from hospitals into local drug and alcohol 
treatment [DAT] services) have been shown to be safe, cost effective, with good uptake and 
treatment outcomes similar to, and in some cases better than, secondary care (18-21). 
In 2013, Project ITTREAT was established within a DAT service and aimed to assess the 
feasibility of delivering an HCV service in the DAT by collecting real world clinical, patient 
reported, health economic and qualitative outcomes (17). Here we report on the qualitative 
study exploring the experiences of DAT clients and staff of Project ITTREAT, assessing the 
facilitators of and barriers to service use and whether the service provided by Project 
ITTREAT overcomes recognised barriers to HCV care 
Methods 
Study setting and intervention background 
Project ITTREAT commenced in Dec 2013 as a two-year project but was subsequently 
extended for a further six years (until Dec 2021). Interviews and focus groups were all 
conducted by an experienced qualitative researcher (CJ) between October 2014 and April 
2016 as a concurrent embedded qualitative study. 
The process of the service set up has been previously described (17). In summary, ITTREAT 
was located at one of the largest urban DAT service in South East England. A full-time, 
experienced hepatitis nurse (equivalent to band 7 in the NHS structure) (MOS) (working 
Monday-Friday) provided blood borne virus (BBV) testing using finger prick dry blood spot 
testing and hepatitis B virus vaccination to DAT attendees. If qualitative HCV PCR was 
positive, individuals were contacted (via phone or in person) and offered HCV quantitative 
PCR/genotype, blood tests, assessment of hepatic fibrosis using a portable FibroScan® 402 
(Echosens) (non-fasting) and HCV treatment, at the DAT, under Hepatologist (SV) 
supervision. Clinics offered were ‘one-stop’ flexible and run on a ‘drop in’ basis.  All 
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participants were provided with a contact phone number for the HCV nurse. DAT staff were 
also trained by the HCV nurse to perform BBV screening. Psychiatric input, opioid 
substitution therapy (OST), social/peer mentor support and a needle syringe programme 
were offered onsite by the DAT. The HCV nurse worked closely with other health care 
professionals both within the community (e.g. GPs and DAT care-co-ordinators) and the 
hospital-based services (e.g. vascular access team, gastroenterology pharmacy team).  
Unique aspects of Project ITTREAT therefore were a dedicated, full-time hepatitis nurse 
based at the DAT who provided a personalised and holistic service in an integrated manner 
effectively linking all components of care. Those with ongoing drug and alcohol use were 
eligible for HCV treatment, as long as they were willing to engage.  
Interviewee recruitment  
Study participants included DAT attendees and staff. DAT attendees were eligible if they had 
been offered and/or were engaged in the HCV service provided there. DAT attendees were 
purposively sampled to include those who had historically declined, were waiting to start, 
were currently receiving and who had completed HCV treatment. Interviews were 
conducted before, during and after DAAs were made available.  
All staff based at the DAT (excluding the HCV nurse) were invited to one of the two focus 
groups where informed consent was taken by the qualitative researcher (CJ).  While all staff 
were invited (by the HCV nurse) to participate in the study, only those available on the dates 
planned for the focus groups were recruited, utilising a convenience sampling approach.  
DAT attendees to the HCV clinic and DAT staff were approached by the HCV nurse, who 
provided a copy of the participant information sheet and, with their consent, passed their 
contact details to CJ. Eligible and interested DAT attendees were contacted by CJ to arrange 
a convenient time for an individual interview, at which time informed consent was taken 
Interviews (for HCV clinic attendees) and focus groups (for DAT staff) took place in a private 
room within the DAT service.  
Data collection 
The interviews and focus groups were semi-structured, with the interviewer following a 
topic guide (see supplementary information). Interviews with DAT attendees lasted 
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between 30 -60 minutes and topics included history of IDU, experience of initial HCV 
diagnosis, barriers and motivators to engaging in HCV testing and treatment, experiences of 
other healthcare services including in the community and areas of future service 
improvement. Each focus group lasted an hour and included topics such as the challenges in 
HCV testing and treatment uptake, experiences of hospital and community-based services 
and areas of future service improvement.  
Data analysis 
Transcripts from DAT attendee interviews were analysed first. Staff focus group transcripts 
were incorporated into the analysis once completed. Thematic content analysis was 
performed using Burnard’s 14-stage method (22). To begin with the verbatim transcripts 
were coded openly to generate as many themes as possible. The themes that emerged were 
partly deductive, reflecting the research objectives, and partly inductive emerging during 
data familiarisation. A thematic framework was then constructed. To ensure reliability, data 
were initially analysed by JS, the themes were then compared and discussed with CJ, to 
develop an overall analytical framework for the DAT attendee interviews and DAT staff 
focus groups.  
Ethical approval 
Ethical approval for the study was obtained (NRES Committee East Midlands - Derby REC ref 
13/EM/0275). All participants gave signed, informed consent.  
 
Results 
Tables 1 and 2 show demographic and additional data of DAT clients interviewed and staff that took 
part in the focus groups. The DAT clients entirely described themselves as white (100%), males (80%) 
with 40% aged 35-44 yrs and 40 % aged 45-54 yrs. Overall 7 (47%) were currently unemployed. All 
were either past (n=12) or current (n=3) PWID. Two had completed successful addiction 
rehabilitation, for the remaining recovery was ongoing. Overall 9 (60%) had either already 
completed or were currently receiving HCV treatment. Of the 15 interviews, 11 were conducted 
from 2014-15 during the transition from interferon to DAA based regimens, with the remaining 
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completed in 2016. The majority of clients interviewed had received/were receiving interferon-
based HCV treatment (7/9, 78%).  
Fifteen staff members took part in the focus groups, equally split amongst males and 
females (seven and eight respectively). The majority, 10 (75%), were aged 45-54 yrs with 14 
(93%) describing themselves as white.  Duration of employment at the DAT ranged from 1 -
20 years. 
Table 1 - Demographics of DAT attendees 
Table 2 - Demographics of DAT staff  
Facilitators of accessing HCV care via Project ITTREAT 
This comprised 4 principal themes and 15 sub-themes (figure 2) 
1) Trusting client-provider relationships 
The close relationship between clients and their keyworker/care-coordinator at the DAT was 
clear from the interviews and focus groups. This relationship acted as an entry point into 
HCV care; staff described initiating discussions around HCV care and then referring clients to 
the on-site hepatitis nurse once they were ready to engage. Interestingly, staff perceived 
themselves as ‘sellers’ of HCV care.  
“Well it’s down to us to sell it isn’t it [HCV testing and treatment]? Because if we don’t sell it, 
it won’t happen. It’s basically that.” (DAT Staff member, focus group 1) 
The relationship between clients and the HCV nurse was central to their engagement with 
Project ITTREAT. Participants valued the ‘non-judgemental’, ‘personal’ and ‘friendly’ 
approach of the HCV nurse. The interviews highlighted the importance of a holistic and 
personalised approach when engaging clients; the HCV nurse supported clients’ housing 
applications and mental health needs as well as their HCV treatment. 
“I mean, I have to say I think [HCV Nurse] is one of the main people behind and she’s, 
she’s so friendly and nice that she just puts you at ease anyway. There’s not like, 
you’re not dealing with fearful doctors with a sense of impending doom on all sides.” 
(Participant 3, 20 months since diagnosis, untreated) 
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Importantly, despite poor engagement with health services, for two participants a trusting 
relationship with their GP facilitated entry into HCV care. 
“I’d prefer to be seen at the doctors…the GP I’ve got now, yeah, she’s really she’s 
brilliant…Yeah, many a time I’ve gone to the surgery and I’ve been in there twenty minutes 
half an hour, just emptying, emptying in front of her. And she’s really good, she listens” 
(Participant 15, 11 years since diagnosis, completed treatment) 
The focus groups also highlighted the importance of the close relationship between DAT 
staff and the HCV nurse, facilitating a greater awareness of HCV within the service. 
“Having someone here in the building just makes a huge difference; to be able to ask 
questions and get information about Hepatitis when people ask things. It just raises, I 
think all of our kind of awareness of it.” (DAT Staff member, focus group 1) 
 Hepatitis C care as part of the recovery pathway  
Both clients and staff perceived HCV treatment as the natural, next step in the recovery 
pathway. Successful recovery from drug and alcohol addiction empowered clients to seek 
HCV treatment. 
“When people have gone into residential, and then one of their next goals that people often 
have, is when they leave residential, is then to address their hepatitis issues.” (DAT staff 
member, Focus group 1) 
“When I got myself clean and thought to myself; now or never. You never know what 
could happen, in the future. While I’m headstrong at the minute; I’ll just go for it.” 
(Participant 4, 7 years since diagnosis, on treatment) 
HCV infection was inextricably linked to drug use; once stable in addiction recovery, 
participants expressed a desire to disassociate themselves from the stigma attached to HCV 
infection.  
“I suppose some of it ties into the stigma again, you know I wanted to be clear and, 
you know, as free from anything drug-related…as quickly as possible.” (Participant 1, 4 
years since diagnosis, completed treatment) 
Following recovery, participants expressed both a greater awareness of the health impacts 
of untreated HCV and a heightened sense of their own mortality. Without withdrawal 
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symptoms, clients were more likely to attribute their physical symptoms to HCV, which 
acted as a motivator to seeking treatment.  
“I didn’t want to have hepatitis, I don’t wanna die young, do you know what I mean. 
Like, I’ve had it for a long time, and you know, I don’t, like, I’m only like 49 now or 48, 
something like that. But, like, I’m not old, do you know what I mean, and I’m not 
young- I’m middle aged. So I wanna, I’d love to have some time without the hepatitis, 
I’d love to get it out of me body cos I’ve seen someone die of hepatitis and it’s not 
very nice.” (Participant 5, 15 years since diagnosis, completed treatment) 
One client reported not having understood the seriousness of HCV until he engaged with 
the DAT and the recovery process. 
‘I didn’t really understand the seriousness of Hep C till I started like seeing...someone at the 
[DAT] about it and then I got linked in with [HCV nurse]. I started realising this isn‘t 
something you can just shrug off like I’ve done for ten years.. (Participant 12, 10 years since 
diagnose, 10 weeks into treatment) 
 
2) Mitigation of previous negative experiences of secondary care 
Clients expressed reluctance to engage in hospital-based health services, for both their 
general health and for HCV treatment, but Project ITTREAT mitigated many of these issues 
for clients and staff. Mistrust, fear and bad experiences of hospitals were widely reported: 
“I don't like hospitals. I only ever go to hospital if I’m dying.” (Participant 11, 6 years since 
diagnosis, untreated) 
 
“It’s the association as well, I think for our client group as well being in hospital- you 
know a lot of negative experiences: you know memories of overdosing and nearly 
dying.” (DAT staff members, focus groups 2) 
 
“And you do hear people talking about their bad experiences: feeling judged up at 
A&E. I think self-worth and self-esteem has got a lot to do with going up to the 
hospital: ‘I’m not worthy of their time’, ‘these other people are- mine’s self-inflicted’, 
‘why should they care about me?’” (DAT staff member, focus group 1) 
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Being able to access HCV care without having to attend the hospital-based services was 
positively welcomed: 
“Down here’s better I think: cos it’s all in one place. You know, it’s all- it’s all in the one 
building. Instead of being up here and then you’ve gotta come down here and then you’ve 
gotta go there and then here; things’ll get confused” (Participant 7, 1 year since diagnosis, 
untreated) 
 
[Talking about hospital service] “Much, much more medicalised, much more; this feels much 
more community orientated. Um, you know, there nurses felt like nurses and…yeah it was 
going to hospital, you know and having your regular appointment at the hospital…I mean it 
felt like that”. (Participant 8, 4 years since diagnosis, untreated) 
Hospital-based bureaucracy emerged as an important system-level barrier, especially the 
inconvenience of travelling to hospital, inflexibility of appointment times and lengthy 
appointment waits. These were overcome by the flexible approach adopted by ITTREAT:  
“If you’re being seen in outpatients at the [Hospital] and you miss an appointment- 
that’s it. Whereas with [HCV nurse] she’ll call you again and again and you can have 
three goes before you see her. Whereas with the [Hospital] they have an 
appointment system that doesn’t work like that.” (DAT staff member, focus group 1) 
 
“I thought it was a little less, err, impersonal. You just feel like you’re a cow being forced 
through, like a sheep dip kind of system in hospitals. But here you know they know your 
name and they’re a little bit more personal with you. I think a little bit more caring cos they 
have a little bit more time” (Participant 2, 1 year since diagnosis, on treatment) 
Staff members also described a lack of coordinated care between hospital Hepatology 
services and the DAT which Project ITTREAT helped alleviate: 
“It’s communication as well: [The hospital department] wouldn’t necessarily have all the 
facts to hand, whereas [HCV nurse] can speak to care coordinators on a one to one” (DAT staff 
member, focus groups 1) 
3) Positive narratives of HCV care 
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Clients and staff members discussed the influence of ‘word of mouth’ stories of HCV 
treatment from peers within the recovery community. Traditionally, negative stories have 
dissuaded clients from seeking treatment, but positive narratives encourage participants to 
engage in care, especially, clients’ experiences with DAAs. 
“[HCV nurse] was just saying- she’s had an uptake in Scottish people- cos they know 
each other in the community and cos one of them has had the treatment with [HCV 
nurse]: now she’s had one or two people from the same little social circle turning up. 
And yeah so, it is word of mouth” (DAT staff member, focus group 1) 
 
“It’s just general, you just sit and talk, but everybody’s raving about this new stuff, 
everybody claims that ‘oh I know someone that’s done it’.” (Participant 14, 6 years since 
diagnosis, on treatment) 
 
“I found out about the new treatment that’s available, and thought I’d wait. And then I 
forgot about it; conveniently shoved it in that place that you don’t think about it, and 
[Hepatitis C nurse] called me and said, ‘do you wanna go up for a trial on this?’ So were just 
waiting to hear… I think it’s here, well it’s through [Hepatitis C nurse] - she’d be able to tell 
you and it’s the shorter treatment and it doesn’t have the depression side effects. And to be 
honest I’d wait years for that treatment, rather than take the risk of having the negative side 
effects...” (Participant 3, 20 months since diagnosis, untreated) 
Barriers to accessing HCV care via Project ITTREAT 
This comprised of 3 principal themes and 8 sub-themes (figure 3) 
1) Lack of stability  
The notion of instability emerged as a central theme in preventing participants from 
accessing HCV treatment whereby social circumstance competed with health needs. This 
included homelessness or lack of permanent accommodation, unemployment, and time 
spent in prison: 
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“But because erm, my life was just chaos at the time- I was homeless, I was trying to hold 
down a job and…yeah it was just sort of really impossible for me to kind of have enough 
consistency to start doing the treatment” (Participant 2, 1 year since diagnosis, on treatment) 
 
“I think accommodation, people’s stability around accommodation and things like that: having to 
have a fridge, you know, a personal space, that sort of thing. Having somewhere where it’s safe to 
have a parcel to be delivered” (DAT staff member, focus group 1) 
Furthermore, emotional instability due to complex mental health problems, lack of strong 
social networks and, in particular, ongoing drug and alcohol use were perceived to be a key 
factor in determining clients’ stability to engage in treatment.  
“It’s not your first priority. Your first priority when you’re out there is to score more 
drugs. Comes above and before everything. So getting rid of a blood borne virus 
which you might catch the next day anyway…fighting a losing battle.” (Participant 11, 6 
years since diagnosis, untreated) 
 
“I think lots of people that are homeless on the streets, there’s this almost, I can only think of 
one word and its cavalier. You know, ‘I know I’ve got Hep C but you know: what’s the point? 
I’m using all these drugs.’ Just to manage my situation in the here and now. And you know, 
treatment options are way down their list of priorities really.” (DAT staff member, focus group 1) 
2) Stigma 
Stigma, relating to HCV diagnosis, led to an initial reluctance among participants to accept 
the diagnosis and therefore a delay in accessing information and treatment. Before 
engaging with the community service, participants reported very little knowledge of the 
health consequences of HCV. Interviewees also described their unwillingness to disclose 
their diagnosis to friends, family members and partners.  
I haven’t told anyone about it [HCV]. Cos I’m frightened of the stigma comin back, do you 
know what I mean? (Participant 5, 15 years since diagnosis, completed treatment) 
One important barrier to engagement with Project ITTREAT that emerged was the stigma 
associated with the physical premises of the DAT. This was particularly evident amongst 
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participants who were stable in recovery, no longer perceiving themselves as “drug addicts”. 
This led some participants to express their preference for a separate, non-DAT-based 
community HCV service. 
“Yeah, I used to have that a lot, kind of walking up the steps at the traffic lights and 
there are kind of loads of cars, kind of gridlock, and you know you’re almost 
advertising yourself as like an addict walking up the steps.” (Participant 13, 2 year since 
diagnosis, completed treatment) 
 
“I think it would be better if they had just a hepatitis place that they concentrate on 
hepatitis. And then you’ve got your drug place, where you go for your methadone, and all 
that. I think it should be, like, separate...” (Participant 5, 15 years since diagnosis, completed 
treatment) 
3) Negative discourse around testing and treatment 
Participants described negative anecdotes from their peers, of hepatitis testing and 
treatment revolving around risk of substance misuse relapse, interferon related physical and 
mental side effects, length of the treatment course and need for liver biopsies. 
“well yeah, getting tested like with the biopsy thing, cos I was told some quite nasty 
things that it gets stuck right into you and it has to cut a bit of your liver out and it’s 
like…yeah it seems sort of like quite painful and quite horrible really.”  (Participant 10, 8 
years since diagnosis, untreated) 
 
[Discussing the risk of relapse] “I really don’t wanna take interferon. I really am 
absolutely petrified of it. Because I’ve, over the last 18 months I’ve built up so much 
of a normal life. My children talk to me as though it never happened…I cannot rock 
that boat.” (Participant 3, 20 months since diagnosis, untreated) 
 
“Yeah, and its side effects, cos back then as well it was all interferon and people were 
telling me it’s like chemotherapy: you’re gonna lose your hair and all sorts. And I was 
thinking, I don’t feel ill- I’m not putting myself through all that” (Participant 14, 6 years 




This qualitative evaluation of Project ITTREAT highlights how our community hepatitis clinic 
successfully facilitated DAT attendees to access HCV treatment, removing barriers, 
specifically those at the provider level (figure 1). The presence of a dedicated provider, 
positive narratives of HCV treatment from peers and stability within drug/alcohol recovery 
were all important facilitators and motivators that enabled DAT attendees to address their 
HCV diagnosis and access treatment. Lack of personal stability, negative stories from peers 
about HCV treatment and stigma remained important barriers to accessing HCV care, 
despite our intervention. An unanticipated barrier for those who had graduated from drug 
use and OST treatment was the stigma generated by locating the community hepatitis clinic 
within the DAT.  
The time period for this qualitative study (Oct 2014 - Apr 2016) spanned the transition from 
interferon-based treatments to combinations of interferon and DAAs and finally interferon-
free DAA regimens. The facilitators and barriers identified therefore reflect this whole time 
period. Most facilitators related to project ITTREAT itself (trusting client provider 
relationship, HCV care as part of recovery process, mitigation of previous negative 
experiences of secondary care) while others such as the theme ‘positive narratives of HCV 
care’ are reflective of both project ITTREAT and the newer treatments, as these are 
inextricably linked. Negative discourse around HCV treatment largely related to the older 
treatments and liver biopsies, whilst stigma attached to the clinic location, the DAT, was 
specific to the ITTREAT project.  Stigma of HCV and lack of stability to engage with HCV 
treatment were general barriers reported in this cohort, not specific to either project 
ITTREAT or the changing treatment landscape.  
A flexible, trusting client-provider relationship helped alleviate patient and provider level 
barriers and was central to DAT attendees engaging with Project ITTREAT. This finding 
closely mirrors those reported previously (19, 23, 24). The importance of this flexible 
approach to delivering HCV care to PWIDs cannot be underestimated. Particularly noted was 
the central relationship between the HCV nurse and DAT attendees, which was crucial in 
client engagement, as also observed by others (24). Being located in the DAT full-time also 
allowed for close working relationships between the HCV nurse and DAT staff, enabling 
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effective working relationships and more holistic provision of care for clients in drug and 
alcohol recovery. This not only raised awareness and the profile of HCV amongst DAT staff 
but also enabled the adoption of a ‘shared-care’ approach and smooth referral between 
services. In summary, these relationships, and the removal of bureaucratic barriers allowing 
for flexible working, created an accessible environment for DAT attendees to engage with 
Project ITTREAT. These findings are corroborated by the ETHOS study, which found that an 
engaged clinician and accessible treatment pathway were key facilitators of engagement 
(16). 
However, while studies have shown that community-based interventions result in an 
increase in HCV treatment, overall treatment uptake remains low (25-27). This could be 
partly related to lack of co-location of HCV screening and treatment, inflexible clinic timings 
and not involving peer mentors (25-27).  ITTREAT provided an integrated test and treat 
service with “drop in clinics” where PWID engaged with the same nurse. In the absence of 
interferon or liver biopsies as barriers to treatment, we anticipate our model of care 
delivery provides an unprecedented opportunity to increase treatment uptake in this cohort 
in the era of DAAs.  
Lack of stability emerged as a major barrier to HCV care and has been reported elsewhere 
(14, 23, 24). This included physical instability (such as housing), psycho-social instability and 
in particular drug and alcohol use. Accessing HCV care became a priority once stability was 
achieved, including those who were on the recovery pathway. The intention to address 
health issues once in recovery has also been reported in a study evaluating the barriers to 
PWIDs accessing sexual health services (28). Thus, by placing health services at the DAT, as 
in Project ITTREAT, services are perfectly placed to respond in a timely manner to clients 
who are ready to engage with HCV (and other health) care during their recovery. This was 
described as ‘timeliness’ by Harris in 2018 and appears to be a generalizable finding (24). 
Identifying these time points and developing an accessible service for clients has the 
potential to improve health outcomes in this cohort.  
The stigma perceived by PWID remains an important barrier to accessing HCV care (29). This 
could be at a personal level (related to drug use) or the discriminatory attitude of health 
care providers (30, 31). This is often coupled with limited education amongst clinicians 
regarding addiction (29). In addition a novel finding from our study revealed the distinct and 
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contrasting attitudes towards the DAT. Whilst some who had graduated from drug use felt 
attending the DAT and integrating with others who were in the early stages of recovery, 
reinforced their successful recovery, others felt it put them at risk of relapse and of being 
unable to escape the label of a ‘drug addict’. This stigma around engagement with the DAT 
was identified previously in a 2012 WHO study (23). It must therefore be acknowledged that 
“one size does not fit all”, and the emphasis should be on the provision of personalised care. 
As suggested by some participants, stigma of the DAT could be overcome by offering an HCV 
service in a ‘half-way house’ somewhere between the hospital and DAT. This was the main 
area of potential service improvement identified by participants. Some DAT attendees 
reported strong relationships with their GP and reported a preference for the anonymity a 
GP surgery provides. There is a growing body of literature demonstrating that HCV 
treatment can be effectively delivered through primary care, with or without OST services 
(14, 19, 32). This is thus a useful and potentially important avenue for future service 
development.  
Additionally, stories shared within the substance misuse community shaped participants’ 
perceptions of HCV testing and treatment. While negative stories were reported in this 
study, these largely referred to the now obsolete interferon-based treatment and liver 
biopsies. At the time of this study, HCV treatment was transitioning from interferon-based 
treatment to DAAs (the majority of the interviewees received interferon-based regimens), 
thus discourse on the new DAAs was limited. Importantly, these peer networks also 
disseminated positive narratives around HCV treatment, motivated others to access care 
and some participants reported hearing positive stories of the new DAAs via the recovery 
community. Previous research has identified the influence of ‘word of mouth’ stories among 
populations of PWIDs (16, 33, 34) and increasing evidence in the literature supports a role 
for peer mentors in improving treatment knowledge and uptake (27, 35-37). With the 
introduction of the FibroScan® for non-invasive assessment of hepatic fibrosis and better 
tolerated pan-genotypic DAAs there is an opportunity to harness the influence of peer 
networks to dispel the negative discourse around HCV testing and treatment. 
Finally, concerns regarding reinfection remains a barrier to initiating HCV treatment 
amongst PWID, particularly for clinicians. However as shown by others (10, 38, 39) 
reinfection rates remain low in PWID (< 3/100 person years) especially if there is timely 
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introduction of opioid substitution therapy. This again emphasises the importance of 
integrated services when engaging PWID in HCV treatment.  
This study had limitations. Participants were initially approached by the HCV nurse who was 
the principal clinician running Project ITTREAT at the DAT. Loyalty to the nurse may have 
biased responses and may have, inadvertently, led to selective recall. Secondly, the client’s 
perspective comes only from DAT attendees of Project ITTREAT, and therefore excludes the 
experiences of DAT attendees not engaged in the HCV treatment service provided by the 
project. Thirdly, DAT staff volunteered to take part in the focus groups, potentially self-
selecting those with the greatest interest or strongest views on HCV services, and again 
potentially clouding responses. Additionally, only staff able to attend on the days of the 
focus groups were recruited, possibly introducing bias. Furthermore, data collection took 
place within the DAT which may have resulted in a potential reporting bias in interview 
responses, although the qualitative researcher was independent to the DAT. Finally, since 
most participants were in recovery and received interferon-based treatment, we were 
unable to assess in detail the impact of recovery status and the advent of DAAs on attitudes 
and perceptions amongst clients and staff. This study was conducted in one geographical 
region of the UK; however, its findings are corroborated by observations from other 
national and international studies (16, 24).  
Future research needs to focus on how best to encourage collaborative working between 
DAT and hepatology communities; raise the profile of community models of care to enable  
national adoption; eliminate the still persisting stigma towards PWID; effectively educate 
PWID and healthcare providers about DAAs; dispel antiquated myths about older 
treatments and liver biopsies and, finally, investigate how or where a ‘half-way house’ HCV 
clinic may be best located.  
In summary this study illustrates the barriers and facilitators amongst DAT staff and 
attendees of a community HCV service embedded within a DAT. This has important 
implications for policy makers and regional ODNs tasked with allocating resources to 
achieve HCV elimination. HCV treatment as part of drug and alcohol recovery pathways is 
now feasible, particularly in light of the new safe and effective DAAs that are increasingly 
available. If HCV elimination is to be achieved, engaging PWID in care by a movement 
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towards community-based services, and away from historic hospital-based settings is 
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1. Majority are PWID with poor engagement with secondary care due to chaotic lifestyle and competing 
priorities  
2. Asymptomatic nature of the disease  
3. Perceived stigmatisation and prior negative experiences with health services  
4. Myths associated with antiviral treatment and liver biopsy 
Provider level  
1. Failure to understand complex needs of PWID  
2. Lack of awareness, hence not a priority for health care professionals  
3. Bureaucratic and inflexible hospital environment  
4. Prejudice and reluctance to treat those with ongoing alcohol and drug use  
5. Misconceptions regarding treatment efficacy and reinfection in PWID  
6. Lack of multidisciplinary approach with suboptimal interactions between addiction specialists and 
Hepatologists 
National level  
1. Restricted access to antiviral drugs  
2. Lack of accurate data on HCV epidemiology 
 
Figure 1 Barriers to care in individuals/PWID with hepatitis C virus infection (14) 
 
















Ex PWID Ongoing Student P/T Youth 
offending service 
White 4 Complete 
002 45-54 
M 

















 White 15-20 Complete 

















White 4 None received  
009 25-34 
M 









Ex PWID  Ongoing Other Voluntary worker White 6 None received 
012 35-44 
M 
Ex PWID  Ongoing Other  Intern – support 
worker (drug & 
alcohol services) 













Ex PWID  Ongoing Unemployed (previously 
roofer) 
White 11 Complete 
*Abbreviations: F/T = full time, P/T = part time, PWID = person who injects drugs, TEFL = teaching 
English as a foreign language, PEG IFN = pegylated interferon, RBV = Ribavirin, SOF = Sofosbuvir, DAC 














Table 2 - Demographics of DAT staff 
ID Age Gender Employment 
status 




001 45-54 F FT Community nurse 14  White 
002 35-44 F FT Community nurse 2  White 
003 45-54 M FT Engagement and recovery 
worker 
>10  White 
004 45-54 F FT Senior community practitioner 
nurse 
8  White 
005 45-54 F PT Community nurse 1 White 
006 45-54 M FT Community charge nurse 9 White 
007 35-44 M FT Community charge nurse 11  White 
008 55-64 M FT Engagement and recovery 
worker 
14  Other 
009 25-34 F Other – bank 
staff 
Community nurse >1 White 
010 45-54 M PT Drug and alcohol care 
coordinator 
1 ½  White 
011 55-64 F FT Community nurse 5  White 
012 45-54 F PT Community charge nurse 20 White 
013 45-54 M FT LGBT support worker 5 White 
014 45-54 F PT Community charge nurse 10 White 
015 45-54 M FT Care co-ordinator 2 ½  White 
* F/T = full time, P/T = part time 
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